Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.73 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | MTOR | P42345 | 6/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487158 | 0.93 | KDR (0.73) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL14214609 | 0.84 | KDR (0.87) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL14214615 | 0.83 | KDR (0.85) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL14214616 | 0.83 | KDR (0.84) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL14214612 | 0.82 | KDR (0.82) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL14214730 | 0.81 | KDR (0.82) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL6489956 | 0.81 | KDR (0.81) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL6480028 | 0.79 | KDR (0.77) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL6478410 | 0.79 | KDR (0.80) | KDRLCKMAPK14IGF1RPIK3CA | |
| SCHEMBL6478730 | 0.79 | KDR (0.77) | KDRLCKMAPK14IGF1RPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-6916797-B2 | α-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2005-07-12 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | TACR1, TACR2, NPSR1 | KDR 1262/4885LCK 1934/4885MAPK14 2247/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | KDR 4/4885LCK 1859/4885MAPK14 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.